UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen

Ysebaert, Carine; Castado, Cindy; Mortier, Marie-Cécile; Rioux, Stéphane; Feron, Christiane; Paolo, Emmanuel Di; Weynants, Vincent; Blais, Normand; Devos, Nathalie; Hermand, Philippe

doi:10.1016/j.vaccine.2021.08.002

Cited by 6 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TbpB-based vaccines could also target Moraxella catarrhalis, thus potentially extending protection to two of the main causes of otitis media and COPD. A vaccine containing USPA2, a protective M. catarrhalis antigen (Ysebaert et al, 2021), and a Protein E-PilA fusion protein from non-typeable H. influenzae that protects colonization in mice and Chinchillas (Ysebaert et al, 2019), is already in development but the cross-protective properties of these antigens have not been fully evaluated.…”

Section: Discussionmentioning

confidence: 99%

Insights from targeting transferrin receptors to develop vaccines for pathogens of humans and food production animals

Ewasechko

Chaudhuri²,

Schryvers³

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

While developing vaccines targeting surface transferrin receptor proteins in Gram-negative pathogens of humans and food production animals, the common features derived from their evolutionary origins has provided us with insights on how improvements could be implemented in the various stages of research and vaccine development. These pathogens are adapted to live exclusively on the mucosal surfaces of the upper respiratory or genitourinary tract of their host and rely on their receptors to acquire iron from transferrin for survival, indicating that there likely are common mechanisms for delivering transferrin to the mucosal surfaces that should be explored. The modern-day receptors are derived from those present in bacteria that lived over 320 million years ago. The pathogens represent the most host adapted members of their bacterial lineages and may possess factors that enable them to have strong association with the mucosal epithelial cells, thus likely reside in a different niche than the commensal members of the bacterial lineage. The bacterial pathogens normally lead a commensal lifestyle which presents challenges for development of relevant infection models as most infection models either exclude the early stages of colonization or subsequent disease development, and the immune mechanisms at the mucosal surface that would prevent disease are not evident. Development of infection models emulating natural horizontal disease transmission are also lacking. Our aim is to share our insights from the study of pathogens of humans and food production animals with individuals involved in vaccine development, maintaining health or regulation of products in the human and animal health sectors.

show abstract

Section: Discussionmentioning

confidence: 99%

Insights from targeting transferrin receptors to develop vaccines for pathogens of humans and food production animals

Ewasechko

Chaudhuri²,

Schryvers³

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The ubiquitous surface protein A2 (UspA2) on Moraxella catarrhalis is very important for its bactericidal activity as well as cross-reactive antibodies. It is usually a negative regulator of TLR3, and IL-1β consequently could reduce the antiviral defence function of the epithelium and cause an increase in viral infections susceptibility (Heinrich et al 2016 ; Ysebaert et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria

et al. 2022

View full text Add to dashboard Cite

Background A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called pathobionts contributes to the severity of the disease. In COVID-19 patients, undetected bacterial co-infections may be associated with the severity of the disease. Therefore, we investigated the implications of bacterial co-infections in COVID-19 cases. Results This is a cross-sectional study that involved archived specimens collected from nasopharyngeal samples of 150 people for COVID-19 screening in Lagos. DNA extraction from the samples was carried out to determine the presence of five respiratory bacterial pathogens using nested real-time PCR, and data were analysed using the Chi-square test. Of the 150 samples collected, 121 (80.7%) were positive for SARs-CoV-2 infection and 29 were negative. The proportion of patients with bacteria co-infection in COVID-19-negative, asymptomatic, and mild cases were 93.1%, 70.7%, and 67.5%, respectively. There was no statistically significant difference between mild COVID-19 conditions and bacteria co-infection (p = 0.097). There was also no significant difference in the nasal carriage of Staphylococcus aureus, Mycoplasma pneumoniae, and Haemophilus spp. However, there was a statistically significant increase in the carriage of Moraxella catarrhalis and Chlamydophila pneumoniae among COVID-19-negative patients when compared with the positive patients (p value = 0.003 and 0.000 for Moraxella catarrhalis and Chlamydophila pneumoniae, respectively). Conclusions The current study shows that bacterial co-infection and superinfection with COVID-19 are not associated with mild and asymptomatic COVID-19 cases in our setting. However, given the high prevalence of Staphylococcus aureus and Mycoplasma pneumoniae among the mild COVID-19 cases seen in this study, early diagnosis and treatment of these bacterial co-infections are still encouraged to mitigate the effect on the severity of COVID-19.

show abstract

“…UspA2 has been reported to have variations in sequence and structure ( Su et al, 2013 ), which may affect antibody recognition and binding. Despite this, anti-UspA2 antibodies raised in mice, rabbits, and guinea pigs were able to induce complement-mediated killing of many, but not all Mcat strains of different origins ( Ysebaert et al, 2021 ). The NTHi-Mcat vaccine containing UspA2 was immunogenic in the phase 1 clinical trial, with a satisfactory safety profile both in healthy individuals and adults with a smoking history ( Van Damme et al, 2019 ).…”

Section: Vaccines Against Ommentioning

confidence: 99%

Otitis media: recent advances in otitis media vaccine development and model systems

Zahid,

Wilson,

Grice

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Otitis media is an inflammatory disorder of the middle ear caused by airways-associated bacterial or viral infections. It is one of the most common childhood infections as globally more than 80% of children are diagnosed with acute otitis media by 3 years of age and it is a common reason for doctor’s visits, antibiotics prescriptions, and surgery among children. Otitis media is a multifactorial disease with various genetic, immunologic, infectious, and environmental factors predisposing children to develop ear infections. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are the most common culprits responsible for acute otitis media. Despite the massive global disease burden, the pathogenesis of otitis media is still unclear and requires extensive future research. Antibiotics are the preferred treatment to cure middle ear infections, however, the antimicrobial resistance rate of common middle ear pathogens has increased considerably over the years. At present, pneumococcal and influenza vaccines are administered as a preventive measure against otitis media, nevertheless, these vaccines are only beneficial in preventing carriage and/or disease caused by vaccine serotypes. Otitis media caused by non-vaccine serotype pneumococci, non-typeable H. influenza, and M. catarrhalis remain an important healthcare burden. The development of multi-species vaccines is an arduous process but is required to reduce the global burden of this disease. Many novel vaccines against S. pneumoniae, non-typeable H. influenza, and M. catarrhalis are in preclinical trials. It is anticipated that these vaccines will lower the disease burden and provide better protection against otitis media. To study disease pathology the rat, mouse, and chinchilla are commonly used to induce experimental acute otitis media to test new therapeutics, including antibiotics and vaccines. Each of these models has its advantages and disadvantages, yet there is still a need to develop an improved animal model providing a better correlated mechanistic understanding of human middle ear infections, thereby underpinning the development of more effective otitis media therapeutics. This review provides an updated summary of current vaccines against otitis media, various animal models of otitis media, their limitations, and some future insights in this field providing a springboard in the development of new animal models and novel vaccines for otitis media.

show abstract

UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen

Cited by 6 publications

References 37 publications

Insights from targeting transferrin receptors to develop vaccines for pathogens of humans and food production animals

Insights from targeting transferrin receptors to develop vaccines for pathogens of humans and food production animals

Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria

Otitis media: recent advances in otitis media vaccine development and model systems

Contact Info

Product

Resources

About